首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Novel multitarget-directed ligands targeting acetylcholinesterase and sigma(1) receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase
【24h】

Novel multitarget-directed ligands targeting acetylcholinesterase and sigma(1) receptors as lead compounds for treatment of Alzheimer's disease: Synthesis, evaluation, and structural characterization of their complexes with acetylcholinesterase

机译:靶向乙酰胆碱酯酶和Sigma(1)受体作为治疗阿尔茨海默病的铅化合物:用乙酰胆碱酯酶的复合物的合成,评价和结构表征作为铅化合物:与乙酰胆碱酯酶的合成,评价和结构表征

获取原文
获取原文并翻译 | 示例
           

摘要

Pleiotropic intervention may be a requirement for effective limitation of the progression of multifactorial diseases such as Alzheimer's Disease. One approach to such intervention is to design a single chemical entity capable of acting on two or more targets of interest, which are accordingly known as Multi-Target Directed Ligands (MTDLs). We recently described donecopride, the first MTDL able to simultaneously inhibit acetylcholinesterase and act as an agonist of the 5-HT4 receptor, which displays promising activities in vivo. Pharmacomodulation of donecopride allowed us to develop a novel series of indole derivatives possessing interesting in vitro activities toward AChE and the sigma(1) receptor. The crystal structures of complexes of the most promising compounds with Torpedo californica AChE were solved in order to further understand their mode of inhibition. (C) 2018 Elsevier Masson SAS. All rights reserved.
机译:热潮干预可能是有效限制多学会疾病等诸如阿尔茨海默病的进展的要求。 这种干预的一种方法是设计一种能够作用于两种或更多种感兴趣靶标的单一化学实体,这被称为多目标定向配体(MTDL)。 我们最近描述了脱癸锌,能够同时抑制乙酰胆碱酯酶并用作5-HT4受体的激动剂,其在体内显示有前途的活性。 钼酮的药物调节使我们能够开发一种具有有趣的体外活性的吲哚衍生物系列的新型吲哚衍生物和Sigma(1)受体。 解决了多次有前景化合物的复合物的晶体结构,以进一步了解其抑制模式。 (c)2018年Elsevier Masson SAS。 版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号